Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
NCT03444038
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
85
Enrollment
INDUSTRY
Sponsor class
Conditions
Tourette Syndrome
Interventions
DRUG:
Valbenazine
Sponsor
Neurocrine Biosciences